Department of Cardiology, Arrhythmology Center, ASL 4 Chiavarese, Lavagna-Genova, Italy.
Cardiothoracovascular Department, Ospedale Policlinico San Martino Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Electrophysiology Unit, Genova, Italy.
Pacing Clin Electrophysiol. 2021 Sep;44(9):1532-1539. doi: 10.1111/pace.14336. Epub 2021 Aug 17.
His bundle pacing (HBP), alone or optimized in association with coronary sinus pacing (HBP+LV) has recently been proposed as an alternative to conventional cardiac resynchronization therapy (CRT). However, there is lack of controlled studies that assessed clinical outcome.
We did a single-center, propensity-score matched, case-control study of comparison of HBP and HBP+LV versus conventional CRT in patients with heart failure (HF) and standard indications for CRT. The study group patients were consecutively enrolled in the year 2019. The control group patients were selected, by propensity score matching, among those CRT implantations performed in the years 2015-2018.
There were 27 patients in each group. In the active group, 12 (44%) patients received HBP alone and 12 (44%) patients HBP+LV pacing. HBP failed in three (11%) patients. In the control group, conventional CRT was achieved in 26 (96%) patients and failed in one. Paced QRS width was shorter in the active than in the control group (128 ± 18 vs. 148 ± 27 ms, p = .004). During a mean of 9.6 months of follow-up, a composite clinical outcome of death, hospitalization for HF or worsening HF occurred in three (11%) in the active group and in four (15%) in the control group, p = .58. No difference was also observed with softer endpoints: NYHA class (1.9 ± 0.7 vs. 2.1 ± 0.7), subjective improvement (74% vs. 74%) and LV ejection fraction (40.7% vs. 40.7%).
Compared with conventional CRT, a shorter QRS width can be obtained with HBP alone or in association with coronary sinus pacing but we were unable to show a better clinical outcome. There is urgent need for large, randomized trials.
希氏束起搏(HBP)单独或与冠状窦起搏优化(HBP+LV)联合应用,最近被提议作为传统心脏再同步治疗(CRT)的替代方法。然而,缺乏评估临床结果的对照研究。
我们进行了一项单中心、倾向评分匹配的病例对照研究,比较了 HBP 和 HBP+LV 与心力衰竭(HF)患者标准 CRT 适应证的传统 CRT。研究组患者于 2019 年连续入组。对照组患者通过倾向评分匹配,选自 2015-2018 年进行的 CRT 植入术。
每组各有 27 例患者。在主动组中,12 例(44%)患者单独接受 HBP,12 例(44%)患者接受 HBP+LV 起搏。有 3 例(11%)患者 HBP 失败。在对照组中,26 例(96%)患者实现了传统 CRT,1 例失败。主动组的起搏 QRS 宽度比对照组更窄(128±18 与 148±27 ms,p=0.004)。在平均 9.6 个月的随访期间,主动组有 3 例(11%)患者发生死亡、HF 住院或 HF 恶化的复合临床结局,对照组有 4 例(15%),p=0.58。更软的终点也没有差异:NYHA 分级(1.9±0.7 与 2.1±0.7)、主观改善(74%与 74%)和左心室射血分数(40.7%与 40.7%)。
与传统 CRT 相比,HBP 单独或与冠状窦起搏联合应用可获得更窄的 QRS 宽度,但我们未能显示更好的临床结局。迫切需要进行大规模、随机试验。